| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Promotes Humoral Autoimmunity by Preventing the Induction of CTL1
*
Research Service, Department of Veterans Affairs Medical Center and Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD 21201; and
Immunology Division, Veterans Affairs Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH 45267.
Neutralization of TNF-
in humans with rheumatoid arthritis or
Crohn’s disease has been associated with the development of humoral
autoimmunity. To determine the effect of TNF- neutralization on
cell-mediated and humoral-mediated responses, we administered
anti-TNF- mAb to mice undergoing acute graft-vs-host disease
(GVHD) using the parent-into-F1 model. In vivo
neutralization of TNF- blocked the lymphocytopenic features
characteristic of acute GVHD and induced a lupus-like chronic GVHD
phenotype (lymphoproliferation and autoantibody production). These
effects resulted from complete inhibition of detectable antihost CTL
activity and required the presence of anti-TNF- mAb for the
first 4 days after parental cell transfer, indicating that TNF-
plays a critical role in the induction of CTL. Moreover, an in vivo
blockade of TNF- preferentially inhibited the production of IFN-
and blocked IFN--dependent up-regulation of Fas; however, cytokines
such as IL-10, IL-6, or IL-4 were not inhibited. These results suggest
that a therapeutic TNF- blockade may promote humoral autoimmunity by
selectively inhibiting the induction of a CTL response that would
normally suppress autoreactive B cells.
This article has been cited by other articles:
|
|
 |
|
  R. Puliaev, I. Puliaeva, L. A. Welniak, A. E. Ryan, M. Haas, W. J. Murphy, and C. S. Via CTL-Promoting Effects of CD40 Stimulation Outweigh B Cell-Stimulatory Effects Resulting in B Cell Elimination and Disease Improvement in a Murine Model of Lupus J. Immunol., July 1, 2008; 181(1): 47 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Anolik, R. Ravikumar, J. Barnard, T. Owen, A. Almudevar, E. C. B. Milner, C. H. Miller, P. O. Dutcher, J. A. Hadley, and I. Sanz Cutting Edge: Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Inhibits Memory B Lymphocytes via Effects on Lymphoid Germinal Centers and Follicular Dendritic Cell Networks J. Immunol., January 15, 2008; 180(2): 688 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. ALESSANDRI, R. SCRIVO, F. R. SPINELLI, F. CECCARELLI, L. MAGRINI, R. PRIORI, and G. VALESINI Autoantibody Production in Anti-TNF-{alpha}-Treated Patients Ann. N.Y. Acad. Sci., September 1, 2007; 1110(1): 319 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maria Lizzio, G. Peluso, A. Zoli, E. Gremese, B. Tolusso, and G. Ferraccioli Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset Ann Rheum Dis, March 1, 2007; 66(3): 427 - 428. [Full Text] [PDF]
|
|
|
|
 |
|
 M DeBandt Lessons for lupus from tumour necrosis factor blockade Lupus, November 1, 2006; 15(11): 762 - 767. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Perez-Garcia, J. Maymo, M. P. Lisbona Perez, M. Almirall Bernabe, and J. Carbonell Abello Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab Rheumatology, January 1, 2006; 45(1): 114 - 116. [Full Text] [PDF]
|
|
|
|
|
|
C Mukhtyar and R Luqmani Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv31 - iv36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Eriksson, S Engstrand, K-G Sundqvist, and S Rantapaa-Dahlqvist Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF{alpha} Ann Rheum Dis, March 1, 2005; 64(3): 403 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Puliaev, P. Nguyen, F. D. Finkelman, and C. S. Via Differential Requirement for IFN-{gamma} in CTL Maturation in Acute Murine Graft-versus-Host Disease J. Immunol., July 15, 2004; 173(2): 910 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G F Ferraccioli and E Gremese Autoantibodies and thrombophilia in RA: TNF{alpha} and TNF{alpha} blockers Ann Rheum Dis, June 1, 2004; 63(6): 613 - 615. [Full Text]
|
|
|
|
 |
|
 M. I. Kafrouni, G. R. Brown, and D. L. Thiele The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection J. Leukoc. Biol., October 1, 2003; 74(4): 564 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R A Mageed and D A Isenberg Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production Lupus, December 1, 2002; 11(12): 850 - 855. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
